AzTrials
AzTrials

Heart FailureNCT06256276

Nutritional Therapy for Autonomic Dysfunction in Elderly Heart Failure Patients

A study testing Whey protein powder and L-carnitine in people with Heart Failure, run by University of Arkansas at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Recent studies suggest that patients with heart failure (HF) may have a reduced ability to control the tone of their blood vessels, heart rate or blood pressure in response to stress. This study will test whether 16 weeks of protein supplements can improve control of blood pressure and heart rate in HF patients. Read more about this study

Who is it for?
Ages 60 to 90 years, women only
Conditions the study is for
Heart Failure
What is being tested?
Whey protein powder and L-carnitine
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
21 participants
Where
1 siteUnited States
Study dates
26 Jul 2016to 1 Feb 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 60 to 90 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Mild to moderate heart failure (NYHA I, II, or III symptomology) as confirmed by study physician

Who cannot join

  • Moderately-severe dementia (MoCA score)
  • Active inflammatory bowel disease
  • Active cancer or chemotherapy in the past year
  • Self-reported allergy to whey protein
  • Documented insulin-dependent diabetes mellitus, or uncontrolled diabetes with hemoglobin A1C >8.5% (collected from medical record)
  • >50mg doses of metoprolol or atenolol daily or more than 12.5mg twice daily of carvedilol
Show all 11Show fewer
  • History of renal failure stage IV or V
  • History of severe orthostasis (>20mm Hg drop in systolic pressure)
  • History of high grade second degree heart block
  • History of arrhythmias (atrial or ventricular, tachy or brady)
  • Other criteria as determined by the study physician

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas, 72205

Other trials in United States

About this study

Recent studies suggest that patients with heart failure (HF) may have a reduced ability to control the tone of their blood vessels, heart rate or blood pressure in response to stress. This study will test whether 16 weeks of protein supplements can improve control of blood pressure and heart rate in HF patients.

Read the detailed description

Heart Failure is defined as "a complex clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill or eject blood." The New York Heart Association classifies heart failure four functional classes: NYHA 1-4, with Class 1 as minimal and Class 4 as the most advanced stage.

As a clinical syndrome, HF can be associated with significant limitations in functional capacity which can be very debilitating in the elderly population. It is a major cause of morbidity and mortality and is the leading cause of hospitalization among older individuals in the United States (1-15), particularly among those aged ≥65 years (16, 18). Nearly 1 million hospitalizations for HF occur each year with rates of hospitalization continuing to rise. Prevalence of heart failure was estimated to be more than 5.8 million in the United States and HF was singled out as an emerging epidemic (17).

Heart failure is associated with autonomic and endothelial dysfunction. Recent studies suggest that patients with HF maybe more prone to having impaired vasomotor and autonomic response to stress (19-29). A reduced ability to increase blood flow or heart rate appropriately in response to demand could limit the functional capacity of these subjects and would contribute to orthostasis (drop in blood pressure on standing). Another factor contributing to orthostasis in these individuals is poor muscle tone in the lower extremities reducing venous flow.

Endothelial dysfunction in HF on the other hand is attributed to decreased production of NO and increased oxidative stress due to neurohumoral activation, release of inflammatory messengers from the myocardium, altered local shear force and resultant atherogenesis (30, 31). The endothelial dysfunction itself causes an increase in the production of cytokines, uncoupling of eNOS and further increases the oxidative stress (32-35). The endothelium helps in regulating the vascular tone by balancing the production of vasodilators and vasoconstrictors in response to various stimuli (36) and its dysfunction would also impair baroreceptor function which in turn would affect cardiac autonomic activity and blood flow.

In our research we hope to improve both autonomic and endothelial function by supplementing protein and carnitine in diet. Studies have shown that when protein is metabolized to the amino acids L-arginine and citrulline, there is increased synthesis of NO (37). L-arginine, a semi-essential basic amino acid, is a precursor in the formation of nitric oxide by the enzyme nitric oxide synthase and directly increases the formation of NO (38). The administration of arginine and/or citrulline in patients in HF has been reported to improve endothelial function. Systolic and diastolic arterial pressures as well as pulmonary arterial systolic pressure have been shown to decrease significantly after administration of arginine or citrulline administration, which in turn improves right ventricular diastolic diameter (37, 39). One clinical study reported improvement in pulmonary artery pressure and right ventricular ejection fraction after two months of oral supplementation with L-arginine or citrulline in patients with HF and right ventricular dysfunction (39). It is hoped that protein supplementation will improve autonomic function by having a positive impact on physiological and biochemical parameters, including nitric oxide synthesis which is expect will improve baroreceptor blood flow, autonomic BP and HR in response to tilt.

Carnitine supplementation of 1g/d for 12 wk in hemodialysis patients significantly reduced systemic inflammation, as reflected by decreases in CRP, IL-1β, and IL-6 (40). In obesity, the mitochondrial abnormalities of reduced fatty acid oxidation, incomplete β-oxidation, and impaired substrate switching from fatty acid to pyruvate were reversed after 8wks of oral supplementation with the same dosage of carnitine (41). It is anticipated the same beneficial effects of carnitine in individuals with HF.

The purpose of this study is to evaluate the effects of 16 weeks of protein supplementation on measures of autonomic regulation of blood pressure and heart rate, as well as physical strength and function in elderly subjects with mild to moderate heart failure (NYHA 1, 2, or 3). Each participant will be randomized to one of two groups (whey protein + L-carnitine or placebos). Study endpoints will be measured at baseline and after 4 months of treatment.

Conditions
Heart Failure
Being tested
Whey protein powder and L-carnitine, Maltodextrin placebo powder and Psyllium Husk capsules
Medical subject headings
Heart Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Whey protein powder and L-carnitineDietary supplement

    Also called Dymatize Elite Whey, Europa Sports Products

    Dietary supplement intervention for 16 weeks

  • Maltodextrin placebo powder and Psyllium Husk capsulesDietary supplement

    Maltodextrin placebo powder and Psyllium Husk capsules

Study groups in NCT06256276
Study groupRoleWhat they receive
Whey protein powder and L-carnitine capsulesExperimentalSubjects will daily consume whey protein powder to supplement normal daily protein intake up to 1.2g protein/kg body weight per day (1 or 2 scoops powder), as well as 2 capsules (1 gram) L-carnitine for 16 weeks.
Receives: Dietary Supplement: Whey protein powder and L-carnitine
Maltodextrin placebo powder and Psyllium Husk capsulesPlacebo comparatorSubjects will daily consume maltodextrin powder as if to supplement normal daily protein intake up to 1.2g protein/kg body weight per day (1 or 2 scoops powder), as well as 2 capsules (1 gram) psyllium husk for 16 weeks.
Receives: Dietary Supplement: Maltodextrin placebo powder and Psyllium Husk capsules

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cardiovascular assessment of blood pressure

    Measuring orthostatic blood pressure

    Measured: Change from baseline to 16 weeks

  2. Cardiovascular assessment

    Measuring heart rate before and after intervention

    Measured: Change from baseline to 16 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Feb 2024
  2. Study start26 Jul 2016
  3. Primary completion11 Jan 2018
  4. Study completion1 Feb 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
21 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06256276
Sponsor's protocol ID
202617
Status last verified
Jan 2024
First submitted
2 Feb 2024
Last updated
13 Feb 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Whey protein powder and L-carnitine in people with Heart Failure, run by University of Arkansas at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cardiovascular assessment of blood pressure (time frame: Change from baseline to 16 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT06256276 | AzTrials